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Abstract
Prostate cancer is the second most common cancer and the fifth leading cause of 
cancer death. The incidence of prostate cancer is rising due to increased screening 
and awareness, and there is epidemiological evidence suggesting an interaction 
among biological and environmental risk factors in the development and progres-
sion of prostate cancer. Vegetables and fruits provide a wide range of antioxidants 
and phytochemicals that have been demonstrated to have a negative, positive, or 
no association with prostate cancer risk. Therefore, it is evident that the effect of 
dietary antioxidants on risk of prostate cancer remains undecided and inconclusive. 
The main focus of this review was to examine recent and past literature of the 
chemoprotective properties of five major groups of phytochemicals against prostate 
cancer development including both in vivo and in vitro findings.
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1. Introduction
Among men worldwide, prostate cancer is the second most common cancer 
and the fifth leading cause of cancer death, with an estimated recorded amount of 
1.3 million cases and 359,000 deaths in 2018 [1]. The incidence of prostate cancer 
is rising due to increased awareness and screening, and it is estimated that 42% of 
prostate cancer cases occur in men over 50 years old [2]. There is epidemiological 
proof that suggests an interaction among several known biological and environ-
mental risk factors in the development and progression of prostate cancer [3]. These 
include age, race, family history, genetic risk, socioeconomic status, and modifiable 
risk factors such as physical activity, obesity, and possibly dietary factors [4].
Oxidative stress defined as an imbalance between prooxidant and antioxidant 
processes, and interference of the oxidation-reduction circuitry is one of the 
many proposed underlying mechanisms of prostate carcinogenesis [5, 6]. There is 
increasing epidemiological data that diet plays a key role in the biology and tumori-
genesis of prostate cancer, and higher intake of the main phytochemical-containing 
diets lowers the risk of the disease [7]. Vegetables and fruits provide a wide range 
of phytochemicals and antioxidants that have been demonstrated to have a positive 
effect on decreasing the incidence or averting the occurrence of prostate cancer [8]. 
Several of these antioxidants may attenuate prostate cancer development, given that 
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oxidative stress from reactive oxygen species and loss of antioxidant enzymes may 
contribute to genomic instability prior to prostate cancer [9].
This paper will review information in the literature on the relationship between 
nutrients with antioxidant properties from the diet, and the risk of prostate cancer.
2. Method of article selection
A literature search was conducted for all English language literature published 
before December 2018. The search was conducted using the electronic databases, 
including PubMed, Embase, Web of Science, and Cochrane Library. The search 
strategy included keywords such as prostate cancer, epidemiology, incidence, mor-
tality, risk factor, selenium, vitamin E, vitamin C, carotenoids, and polyphenols.
The authors include many interventional and observational studies that have 
reported findings of dietary antioxidants, prostate cancer incidence, and progres-
sion. The majority of these studies focused on vitamins E and C, carotenoids, 
specifically beta- and alpha-carotene and lycopene, phenols including tea and 
coffee, and the flavonoids, as well as selenium.
3. Vitamin E and prostate cancer
Vitamin E is a potent lipid-soluble antioxidant, which is well recognized for 
safeguarding the body against free radical-mediated peroxidative damage. It is 
a naturally occurring essential vitamin mainly found in foods such as nuts, oils, 
fruits, and vegetables and is available as a dietary supplement. Vitamin E scavenges 
highly reactive free radical species such as hydroxyls, superoxides, lipid peroxyls, 
hydroperoxyls, and nitrogen radicals; and prevents lipid peroxidation related to 
carcinogen-induced DNA damage [10].
It is known that a deficient antioxidant defense system can result in oxidative 
stress. As such, increased levels of reactive oxygen species over time may have an 
etiological role in the development of malignancies such as prostate cancer [11]. 
Vitamin E may therefore be considered as adjuvant therapy for the prevention of 
prostate cancer [12]. However, despite emerging evidence supporting vitamin E as a 
powerful antioxidant, its effect on prostate cancer risk remains poorly understood.
Two categories of vitamin E compounds exist: tocopherols (α, β, γ, and δ-Toc) 
and tocotrienols (α, β, γ, and δ-T3) [12]. Despite structural differences between 
both categories, tocopherols and tocotrienols each have sufficient antioxidant 
properties [12].
3.1 Alpha-, gamma-, and delta-tocopherols
Alpha-tocopherol accounts for the most abundant and active isoform of vitamin 
E in human tissues and is the most widely used in dietary supplements [10]. Alpha-
tocopherol terminates free radical chain reactions by transferring hydrogen protons 
to free radicals yielding nonradical products [13]. Fairly stable alpha-tocopheroxyl 
radicals are generated, which do not react with polyunsaturated fatty acids but with 
each other or couples with other free radicals to form nonradical products [13]. The 
generation of nonradical products by vitamin E may therefore provide a protec-
tive effect against free radical-mediated cell membrane damage and consequently 
reduces mutagenesis and carcinogenesis.
A number of studies have reported findings on vitamin E supplementation 
(alpha-, gamma-, and delta-tocopherols) and risk of prostate cancer [14–18]. 
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Notably, in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), 
daily supplementation of alpha-tocopherol (50 mg) reduced the risk of prostate 
cancer [17] and moderate dose decreased posttrial mortality [15]. However, a 
follow-up of the Physicians Health Study II, a large-scale randomized trial, sug-
gested that vitamin E supplementation had no immediate or long-term effect on the 
incidence of prostate cancer (HR 0.99; 95% CI: 0.89–1.10) [14]. Conversely, find-
ings from the large-scale selenium and vitamin E cancer prevention trial (SELECT) 
demonstrated that the risk of prostate cancer was significantly increased with 
dietary vitamin E supplementation containing alpha-tocopherol [16]. However, 
it was found that the incidence of prostate cancer did not increase in men who 
received combination therapy of vitamin E and selenium [19]. As such, it can be 
speculated that there may be a synergistic effect between both antioxidants which 
attenuates prostate cancer risk [19]. The increased risk of the disease associated 
with vitamin E therapy could be attributed to the disturbance of the normal physi-
ological balance of vitamin E isomers by the high dosage of alpha-tocopherol, which 
may result in depletion of other important isomers such as gamma-tocopherol [20].
Studies have supported that gamma-tocopherol may have more superior 
chemopreventive effects than alpha-tocopherol, considering its stronger anti-
inflammatory and antinitrative effects [12]. However, it is important to note that 
analysis of 15 prospective studies involving data for prostate cancer cases and 
controls and using risk estimation by multivariable-adjusted conditional logistic 
regression found that gamma-tocopherol was not associated with risk of aggressive 
prostate cancer, and the latter was inversely associated with alpha-tocopherol [21]. 
As such, it was suggested that the protective effect against prostate cancer may be 
lost with impaired balance of vitamin E isomers [20]. Findings from the SELECT 
trial were later recapitulated, as alpha-tocopherol was found to upregulate prostate 
cancer cell proliferation in the early stages of the disease [22]. It was found that 
premalignant rather than benign or malignant prostate cells had increased prolif-
eration in response to vitamin E [22]. These data indicate that the effect of vitamin 
E antioxidant activity may be dependent on the stage of the prostate cells in the 
tumor development process [22]. Conversely, it was later found that combination 
therapy of delta-tocotrienol and gamma-tocopherol was efficacious in inhibiting 
the proliferation of prostate cancer cells by apoptosis and cell cycle arrest in the G1 
and G2/M phases of the cell cycle [12].
A recent study conducted on mice revealed that delta-tocopherol and not alpha-
tocopherol blocks the activation of the Akt pathway which drives tumorigenesis, 
inhibiting the survival of prostate cancer cells [23]. Another study which supports 
the chemopreventative activity of delta-tocopherol is that of Wang et al. which 
reported a novel mechanism by which this antioxidant inhibits prostate cancer cell 
growth by the attenuation of EGF/IGF-induced activation of Akt on T308 [24]. 
In examining the efficacy of other tocopherol, gamma-tocopherol (0.3% in diet) 
supplementation was found to significantly reduce the development of mouse 
prostatic intraepithelial neoplasia lesions and 2-amino-1-methyl-6-phenylimidazo 
[4,5-b] pyridine-induced elevation of nitrotyrosine, 8-oxo-deoxyguanosine, p-Akt, 
Ki-67 and COX-2, and the loss of Nrf2 and PTEN [25].
There is supporting evidence that gamma-tocopherol significantly inhibits the 
growth of human prostate PC-3 tumor cell line by decreasing progression into the 
S-phase, upregulation of transglutaminase 2 and downregulation of (TG2), and 
downregulation of cyclin D1 and cyclin E levels [26]. These findings suggest that dif-
ferent isoforms of vitamin E may differ in their influence on prostate cancer risk and 
that alpha-tocopherol supplementation alone may increase the risk of the disease.
It was reported that the association between vitamin E and prostate cancer risk 
may be linked to genetic variation in genes that regulate antioxidant and vitamin E 
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metabolism [18, 27]. Furthermore, it was found that genetic variation in SOD genes 
responsible for detoxifying superoxide free radicals and protecting cells from oxida-
tive stress may be associated with an increased risk of high-grade prostate cancer 
and disease recurrence [18]. Similarly, it was shown that single nucleotide polymor-
phisms (SNPS) in genes associated with vitamin E metabolism such as SEC14L2, 
SOD1, and TTPA may influence an individual’s response to vitamin E supplementa-
tion and associated prostate cancer risk [28]. As such, inherited genotypes may 
confer prostate cancer risk.
It is therefore anticipated that clinical trials will be undertaken with vitamin E 
isomers combination therapy for further assessment of prostate cancer risk. It may 
be useful to conduct more studies including isomers other than alpha-tocopherol. 
Men with a strong family history of prostate cancer should undergo genetic 
testing, to identify antioxidant gene mutations that may be implicated in prostate 
cancer.
4. Carotenoids and prostate cancer
Fruits and vegetables supply dietary carotenoids, which are potent antioxidants 
as they modify cell growth and induce apoptosis [8]. Epidemiological studies 
indicate that consuming more fruits and vegetables containing plant carotenoids 
such as beta-carotene and lycopene may decrease the risk of prostate cancer as 
indicated by an inverse association [21, 29–31]. In addition to these two carotenoids, 
alpha-carotene, beta-cryptoxanthin, zeaxanthin, and lutein are commonly studied 
because of their potential protective benefit, although lycopene and, to some 
extent, beta-carotene have demonstrated so far the strongest evidence while that of 
the others have proven inconclusive [32, 33].
Carotenoids possess distinctive antioxidative properties including the protection 
of important biomolecules such as DNA from free radicals [34]. Peto et al. in 1981 
hypothesized that β-carotene from vegetables and fruits could possibly decrease 
incidence rates of human cancers [35], and subsequently, there have been a number 
of epidemiological studies addressing this topic [7, 36, 37]. For many years, caro-
tenes such as alpha-carotene and beta-carotene have been investigated relating to 
prostate cancer risk, but the results have proved mostly inconclusive.
4.1 Beta-carotene
Several epidemiological studies have investigated the relationship between 
beta-carotene and prostate cancer risk [38–48]. In the Alpha-Tocopherol, Beta-
Carotene Cancer Prevention Study, subjects receiving beta-carotene supplementa-
tion had a 23% increase in prostate cancer incidence and 15% higher mortality 
from the disease [17]. However, during the postintervention follow-up, the effect 
of supplemental beta-carotene was no longer evident (RR 1.01, 95% CI: 0.96–1.05) 
[44]. In a case-control study involving men with primary histologically confirmed 
prostate cancer and population-based controls, beta-carotene (OR 0.60, 95% CI: 
0.47–0.97) and alpha-carotene (OR 0.67, 95% CI: 0.47–0.97) were inversely associ-
ated with the risk of prostate cancer. Similarly, dietary beta-carotene intake had a 
protective effect for prostate cancer (RR 0.30, 95% CI: 0.13–0.66) among subjects 
younger than 68 years of age in a case control study conducted in the United States 
[47] (Table 1) and another in Japan [43]. In a recent study, circulating beta-carotene 
(RR 0.55, 95% CI: 0.28–1.08) and alpha-carotene (RR 0.31, 95% CI: 0.15–0.63) were 
inversely associated with risk of high-grade prostate cancer, especially among those 
with specific somatic variations [39] (Table 1).
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There are epidemiological studies that have found no protective effect of caro-
tenes on prostate cancer risk [7, 21, 44–50]. In a recent case-control study involving 
incident prostate cancer patients, no statistically significant was observed for 
dietary beta-carotene intake as well as for alpha-carotene and beta-cryptoxanthin 
[45]. In the Japan Collaborative Cohort study, beta-carotene had no protective effect 
Method Name of 
author(s)
Year of 
study
Carotenoids Risk 95% CI P.R.E 
outcome
Case-control
Mettlin et al. 
[47]
1989 β-carotene 
(sup.)
RR = 0.60 0.47–0.97 40%
Nordstrom 
et al. [43]
2016 β-carotene 
(diet)
α-carotene 
(diet)
Lycopene 
(diet)
RR = 0.31
RR = 0.34
RR = 0.55
0.15–0.63
0.18–0.66
0.28–1.08
69%
66%
45%
Van Hoang 
et al. [45]
2018 Lycopene 
(diet)
OR = 0.46 0.27–0.77 54%
McCann 
et al. [66]
2005 β-carotene 
(diet)
α-carotene 
(diet)
Lycopene 
(diet)
OR = 0.53
OR = 0.67
OR = 0.62
0.36–0.79
0.47–0.97
0.37–0.81
47%
33%
38%
Cohort
Umesawa 
et al. [46]
2014 α-carotene 
(diet)
OR = 0.50 0.26–0.98 50%
Karppi et al. 
[50]
2012 β-carotene 
(serum)
RR = 2.29 1.12–4.66 129%
Zu et al. [54] 2014 Lycopene 
(diet)
HR = 0.72 0.56–0.94 28%
Giovanucci 
et al. [53]
2002 β-carotene 
(diet)
0.84 0.73–0.96 16%
Randomized control trial
Virtamo 
et al. [44]
2003 β-carotene 
(diet)
RR = 1.07 1.02–1.12 7%
Meta-analysis
Catano et al. 
[56]
2018 β-carotene 
(diet)
OR = 0.94 0.89–1.00 6%
Rowles et al. 
[58]
2017 β-carotene 
(serum)
RR = 0.88 0.79–0.98 12%
Key et al. 
[21]
2015 β-carotene RR = 0.65 0.46–0.91 35%
Wang et al. 
[33]
2015 α-carotene 
(diet)
Lycopene 
(diet)
RR = 0.87
RR = 0.86
0.76–0.99
0.75–0.98
13%
14%
RR = relative risk, CI = confidence interval, P.R.E = percentage relative effect, Sel. Sup = selenium supplement.
Table 1. 
Showing studies on the effect of carotenoids on prostate cancer.
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as there was no association with prostate cancer risk [46]. However, there are stud-
ies that have reported an adverse rather than a protective effect of beta-carotene on 
prostate cancer. In the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) cohort 
study conducted in Japan among middle-aged men, the highest levels of serum 
beta-carotene resulted in a 2.29-fold (RR 2.29, 95% CI: 1.12–4.6; P = 0.023) higher 
risk of prostate cancer compared to participants with lowest levels of the antioxi-
dant [50]. In the 18-year postintervention follow-up of the Alpha-Tocopherol, Beta-
Carotene Cancer Prevention Study, beta-carotene increased the posttrial prostate 
cancer mortality (RR 1.20, 95% CI: 1.01–1.42) [15] (Table 1). Thus, the effect of 
beta-carotene remains inconclusive and may involve an adverse effect where high 
serum concentrations may elevate prostate cancer risk and mortality.
4.2 Lycopene
Lycopene has been reported to possess more effective antioxidant properties 
compared to the carotenes and alpha-tocopherol [51]. Lycopene in the form of 
tomato-based products and to a lesser extent as a supplement is extensively studied 
with regards to risk of prostate cancer; however, the clinical evidence is inconclu-
sive. In the prostate, lung, colorectal, and ovarian cancer screening trials, lycopene 
consumption decreased the risk of prostate cancer particularly in men with fam-
ily history [52]. Similarly, in the Health Professionals Follow-Up Study, lycopene 
consumption was significantly associated with decreased prostate cancer risk (RR 
for high vs. low quintiles 0.84, 95% CI: 0.73–0.96; P = 0.003), and tomato sauce 
consumption had a greater reduction [53] (Table 1). Other prospective studies have 
reported that circulating levels of lycopene were inversely associated with high-
grade prostate cancer (RR 0.55, 95% CI: 0.28–1.08) [39]; dietary intake of lycopene 
decreased the risk of lethal prostate cancer by lowering the degree of angiogenesis 
in the tumor [54], and lycopene consumption was associated with lower prostate 
cancer-specific mortality among men high-risk disease [55].
A number of meta-analysis sought to examine the efficacy of lycopene intake in 
primary prevention of prostate cancer. In a recent meta-analysis of 27 studies (22 
were case studies), a statistically significant, though weak inverse association, was 
found between prostate cancer and lycopene [56]. In another systemic review and 
meta-analysis, circulating lycopene levels between 2.17 and 85 μg/dL were inversely 
associated with risk of prostate cancer; however, there was no linear association 
with levels greater than 85  μg/dL [57]. Further supporting evidence of the protec-
tive effect of lycopene intake was demonstrated in a recent meta-analysis of 42 
studies where higher circulating and dietary lycopene levels were inversely associ-
ated with a 12% risk of prostate cancer but not with the advanced disease [58]. 
Other supporting evidence involves meta-analysis by Key et al. where lycopene 
though not associated with overall prostate cancer risk results in a 36% significantly 
lower risk with aggressive disease [21]; and a meta-analysis of 34 studies showed an 
association between reduced prostate cancer risk and dietary and blood lycopene 
levels [33]. Furthermore, Mariani et al. reported no overall benefit of decreasing the 
rate of high-grade prostatic intraepithelial neoplasia (HGPIN) progression from a 
6-month lycopene supplementation [59].
Possible pathways involving multiple mechanisms exist through which lycopene 
intake may reduce prostate cancer risk. Lycopene attenuates prostate cancer risk 
by modulating the expression of genes such as EGFR, CDK7, BCL2, and IGF-1R 
which are related to growth and survival [60]. Another study showed that lycopene 
increases the expression of BCO2, a tumor suppressor which mediates the inhibition 
of NF-κB signaling [61]. There is also evidence that lycopene can inhibit the prolif-
eration of prostate cancer cell via PPARγLXRα-ABCA1 pathway [62]. Additionally, 
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lycopene decreases prostate cancer cell proliferation partly by normal inhibition of 
cell cycle progression [63] and promotes cell cycle arrest in the G0/G1 phase [64]. 
The chemoprevention mechanism of lycopene could be the regulation of proteins 
involved in apoptosis, cytoprotection, growth inhibition, antioxidant responses, the 
Akt/mTOR cascade, and androgen receptor signaling [65].
4.3 Alpha-carotene and beta-cryptoxanthin
Other carotenoids such as alpha-carotene and that beta-cryptoxanthin have 
been investigated for possible association with prostate cancer risk. In a case control 
study, there was reduced risk of prostate cancer with lutein (OR 0.55, 95% CI: 
0.37–0.81) and alpha-carotene (OR 0.67, 95% CI: 0.47–0.97) [66]. Nordström et al. 
found that circulating levels of alpha-carotene (RR 0.31, 95% CI: 0.15–0.63) were 
associated with decreased risk of prostate cancer [39]. Similarly, alpha-carotene 
intake was associated with decreased risk of prostate cancer (RR 0.87, 95% CI: 
0.76–0.99) [33]. Further, a meta-analysis of 34 studies suggests that dietary  
alpha-carotene intake was associated with reduced risk of prostate cancer [14], and 
a study by Schuurman et al. showed similar findings for beta-cryptoxanthin [7].
However, in a case-control study conducted in Vietnam, there was no statisti-
cally significant association between prostate cancer risk and intake of alpha-
carotene, beta-cryptoxanthin, zeaxanthin, and lutein [44]. Similarly, in the Japan 
Collaborative Cohort study, dietary alpha-carotene intake was not associated with 
risk of prostate cancer [46]. The absence of the association of dietary intakes of 
lutein, beta-cryptoxanthin, and zeaxanthin with prostate cancer risk requires 
confirmation in future studies.
5. Polyphenols and prostate cancer
Dietary polyphenols (PPs) have gained much traction over the last years for their 
potential as reliable chemopreventive and antitumor agents. This was partly due to 
their presence in a range of foods and beverages commonly consumed by humans 
including fruits, vegetables, coffee, tea, and wine [67, 68]. In terms of chemical 
structure, polyphenols are compounds with at least one aromatic ring with one or 
more hydroxyl group attached [68]. They are grouped into four different classes 
based on their chemical structure and orientation of the number of phenolic rings 
bound to each other. These four classes are as follows: phenolic acids, flavonoids, 
stilbenes, and curcuminoids [67]. Phenolic acids are found in all plant materials and 
account for 30% of all polyphenols consumed. They are found mainly in acidic-
tasting fruits, coffee, and green tea. As the most abundant group of polyphenols, 
flavonoids account for 60% of all polyphenols consumed by humans. Good sources 
of flavonoids include berries, black tea, all citrus fruits, and wine. Together, phe-
nolic acids and flavonoids are the most abundant dietary polyphenols consumed by 
humans and, consequently, are the most studied with regard to their health benefits 
to conditions including cancer.
5.1 Coffee
There are studies that have investigated the relationship between coffee con-
sumption and risk of prostate cancer [55, 69–75]. There are those which have found 
an inverse relationship between coffee consumption and risk of prostate cancer 
[73–75]. The “Coffee Consumption and Prostate Cancer Risk Progression in Health 
Professionals Follow Up” report shows that there is a lower risk for prostate cancer 
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and significant association for reduced lethal and advanced cancer diagnosis in 
participants who consumed six or more cups of coffee per day. There was an inverse 
association for regular (each one cup per day increment: RR 0.94, P = 0.08) and 
decaffeinated coffee (RR 0.91, P = 0.05) [71].
In the Collaborative Prospective Cohort study conducted in the United Kingdom 
between 1970 and 1973 and followed up after 34 years, there was an inverse associa-
tion between coffee consumption and risk of high-grade prostate cancer, but not 
the overall risk of the disease [70]. Notably, adjusting for social class and age, higher 
coffee consumption (three or more cups of coffee) was associated with significantly 
reduced risk of high Gleason grade prostate cancer compared with noncoffee drink-
ers [70]. Similarly, in a population cohort study, men with highest coffee consump-
tion (>3 cups per day) had a 53% lower risk of prostate cancer compared with those 
with lower consumption (<2 cups per day) [72]. Another study supporting the 
potential beneficial effect of coffee consumption is a population-based case-control 
study reported by Russnes et al. where high coffee consumption (>6 cups per 
day) was associated with reduced risk of high grade (OR 0.45, 95% CI: 0.22–0.90; 
P < 0.05) and fatal prostate cancer [76]. In a recent population-based case-control 
study in a single institution in Italy, multivariate logistic regression demonstrated 
that both ferulic acid (OR 0.30, P < 0.05) and caffeic acid (OR 0.32, P < 0.05) were 
associated with decreased risk of prostate cancer, and higher dietary intake of the 
latter may be associated with reduced risk of the disease [67].
However, population-based study reported by Arab et al. using data from the 
North Carolina-Louisiana Prostate Cancer Project showed no association between 
decaffeinated or caffeinated coffee (4 cups per day) and highly aggressive prostate 
cancer (OR 0.92, 95% CI 0.61–1.39) [69] (Table 2). Similarly, in a most recent 
European study, there was no evidence of association for risk of total prostate can-
cer or cancer by grade, grade or fatality, and consumption of total, decaffeinated, 
or caffeinated coffee [77]. The findings of these studies bring attention to potential 
anticancer effect of polyphenols in coffee in reducing progression and metastasis of 
prostate cancer. However, some studies show no association with reduced nonlethal 
or advanced prostate cancer.
5.2 Green tea
Green tea (GT) is one of the most widely studied source of phenolic acids such 
epigallocatechin-3-gallate (EGCG), epicatechin-3-gallate (ECG), and epicatechin 
(EC). There are a number of studies that have investigated the relationship between 
risk of prostate cancer and green tea [78–82], and preclinical, clinical, and epide-
miological data suggest that green tea catechins may reduce prostate cancer risk 
[83]. In a recent case-control study of Chinese men, epigallocatechin 3-gallate and 
green tea reduced the risk of prostate cancer; however, the authors indicated that 
these results should be replicated in larger cohort or case-control studies [84]. 
In a systematic review conducted by Cui et al., green tea catechins significantly 
decreased prostate cancer in high-grade prostatic intraepithelial patients (7.60 vs. 
23.1%, RR 0.39, P = 0.044) [82]. In another systematic review and meta-analysis 
study involving three randomized controlled trials and seven observational studies, 
there was a linear association between green tea catechins consumption (>7 cups 
per day) and risk of prostate cancer [78].
There is further evidence of the chemopreventative effect of green tea. In 
a recent case-control involving Vietnamese men, increasing tea consumption 
(>500 ml/day) was found to be associated with decreased risk of prostate cancer 
[84]. Similar findings were reported in a case-control study of Algerian men, 
although the results were borderline statistically [80]. In one of the first clinical 
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studies to examine the effect of polyphenols (from green tea) on prostate cancer, 
Betuzzi and colleagues showed that green tea consumption reduces the incidence of 
prostate cancer in men with high-grade prostate intraepithelial neoplasia (HGPIN). 
HGPIN is the most likely precursor to prostate cancer, and this study demonstrated 
that 30% of men with HGPIN would develop prostate cancer 1 year after biopsy 
[85]. In this double-blind placebo-control study, the green tea consumption group 
had a 3% incidence rate, while the placebo-treated group had 30% [85]. In a follow-
up study by the same authors 2 years later, men in the green tea consumption group 
had lower incidence of prostate cancer compared with those in the nontreatment 
group [86].
There have being inconsistent results that do exist with regards to the che-
mopreventive capacity of green tea. For instance, one study showed a decreased 
risk of prostate cancer in a multisite case-control study in which participants 
consumed two cups or more of tea per day [87]. In another study, no associa-
tion between tea consumption and prostate cancer risk was found [88]. In both 
studies, there was no association with prostate cancer and coffee consumption. 
In a large cohort European Study reported by Sen and colleagues, no association 
was observed for tea consumption and risk of prostate cancer by grade, stage, or 
fatality [77].
Initially, polyphenols were thought to eliminate cancer cells only through direct 
radical scavenging in a random manner. However, they were found to have moder-
ate efficiency in this function, inferring that more complex action must be at work 
Method Name of 
author(s)
Year of 
study
Sample RR 95% CI P.R.E 
outcome
Cohort
Shafique 
et al. [70]
2012 Tea (>7 cups/
day)
HR = 1.50 1.06–2.12 50%
Wilson 
et al. [71]
2011 Coffee (>6 cups/
day)
RR = 0.82 0.68–0.98 18%
Sen et al. 
[77]
2019 Coffee (375 ml/
day)
Green tea 
(106 ml/day)
HR = 1.02
HR = 0.98
0.93–1.27
0.90–1.07
2%
2%
Case-control
Russnes 
et al. [76]
2016 Coffee (6 cups/
day)
OR = 0.45 0.22–0.90 55%
Lee et al. 
[81]
2017 Green tea OR = 0.60 0.37–0.98 40%
Kikuchi 
et al. [88]
2006 Green tea (> 5 
cups/day)
HR = 0.85 0.50–1.43 15%
Observational
Arab et al. 
[69]
2012 Coffee (>4 cups/
day)
OR = 0.92 0.61–1.39 8%
Meta-analysis
Zong et al. 
[74]
2014 Coffee 
(moderate)
RR = 0.92 0.85–1.00 8%
RR = relative risk, CI = confidence interval, P.R.E = percentage relative effect, Sel. Sup = selenium supplement.
Table 2. 
Showing studies on the effect of coffee and green tea on prostate cancer.
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in eliminating cancer cells. Further investigations proved that polyphenols employ 
biological methods in providing cancer prevention and even elimination, such as 
binding to multiple cellular proteins and regulating signal transduction. Alterations 
in signal pathways affect multiple processes that hinder cancer initiation, progres-
sion, and metastasis [89]. Among green tea catechins, epigallocatechin-3-gallate 
(EGCG) is widely investigated for its cancer preventive properties. In a recent 
study, the difluoro analog, called (-)-5,7-difluoro-epicatechin-3-O-gallate and 
(-)-epicatechin-3-O-gallate from green tea dose-dependently, inhibits tumorigen-
esis during initiation, promotion, and progression in low-metastatic LNCaP and 
high-metastatic PC-3 prostate cancer cells [90]. There is also recent evidence that 
green tea catechins contribute to the inhibition of prostate carcinogenesis by modi-
fying miRNA expression and their target mRNAs, as well as acting as epigenetic 
modulators [91]. Epicatechin-3-O-gallate and theaflavins have been found to reduce 
the rate of cell growth in DU 145 human prostate cancer cells [92]. The inhibition of 
proliferation in the human prostate cancer DU145 cells by tea polyphenols may be 
associated with reduction in the expression of the surviving gene [93].
The extensive methylation of green tea polyphenols and low bioavailability 
limits their chemopreventive activity. A combination of green tea polyphenols and 
a methylation inhibitor quercetin inhibit growth and proliferation in androgen-
sensitive LAPC-4 prostate cancer cells. There was also evidence of stimulation of 
apoptosis and inhibition of phosphatidylinositol 3-kinase/Akt signaling [14]. More 
in-depth studies have demonstrated that green tea polyphenols induced p53-depen-
dent and p53-independent apoptosis in human prostate cancer LNCaP cells by two 
distinct pathways. One pathway involved the inhibition of the survival pathway 
where there is Akt deactivation and loss of BAD phosphorylation, while in the 
other, there is FAS upregulation via activation of c-jun-N-terminal kinase resulted 
in caspase-8 activation, FADD phosphorylation, and truncation of BID [94]. There 
is documentation of other molecular mechanisms by which green tea polyphenols 
trigger death and apoptosis of human prostate cancer cells via inhibition histone 
deacetylase, irrespective of their p53 status [6].
6. Selenium and prostate cancer
Selenium (Se) is a natural nutrient which can be found in different types of 
food. The human body utilizes a trace amount of this mineral in order to function 
optimally. It is reported to have powerful antioxidant properties which prevent 
and reduce oxidative stress. Selenium is an essential micronutrient that functions 
as a redox gatekeeper through its incorporation into proteins to alleviate oxidative 
stress in cells [95]. It also plays a crucial role in development and a wide variety of 
other physiological processes including effect immune responses, metabolism, and 
thyroid function [96, 97]. This has been attributed to selenium’s ability to reduce 
DNA damage and oxidative stress, boost the immune system, and destroy cancer 
cells. The nutritional status of this metalloid has been difficult to assess via food 
intake data alone because many factors influence its presence in the food chain [98]. 
Regular adult intakes of at least 40 μg/day are required to support the maximal 
expression of the selenium enzymes, and perhaps as much as 300 μg/day to reduce 
risks of cancer is needed [99].
A number of randomized intervention trials and epidemiological studies suggest 
that prostate cancer risk may be decreased by selenium intake [100–105]. Studies 
from 2008 to 2014 (Table 3) have shown that selenium supplementation may have 
some level of a protective role against prostate cancer. In the Nutritional Prevention 
Cancer Study (a multicenter, double-blind, randomized, placebo-controlled cancer 
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prevention trial), oral selenium supplementation (200 μg of selenium per day) 
lowers the incidence of prostate cancer (RR 0.37, 95% CI: 0.18–0.71, P = 0.02) 
[106]. Follow-up from this study reported 2 years later found that selenium supple-
mentation reduced the incidence of localized and also advanced prostate cancer 
disease [106].
In the selenium and vitamin E cancer prevention trial (SELECT), there was 
decrease in prostate cancer risk with either vitamin E or selenium supplements 
[107]. In a follow-up from this study, there was an absolute elevation of the risk of 
prostate cancer (per 1000 person-years) that was 0.8 for selenium, 1.6 for vitamin 
E, and 0.4 for the combination [16]. Chan and colleagues conducted a case-cohort 
study of participants in SELECT, randomized to placebo, vitamin E and selenium. 
They reported that selenium- or vitamin E variants may influence the overall 
and high-grade risk of prostate cancer and could possibly modify the patient’s 
response to either selenium or vitamin E supplementation [28]. Furthermore, 
from the SELECT trial involving a stratified case-cohort sample of incident 
prostate cancer cases, elevated high-grade prostate cancer risk was observed in 
men supplemented with high-dose alpha-tocopherol and selenium, possibly due 
to interaction between selenium (or selenomethionine) and alpha-tocopherol 
[41]. The results of the SELECT study showed that it failed to demonstrate 
any significant decrease in prostate cancer ascribable vitamin E and selenium 
supplementations.
Researchers found it useful to investigate any possible association between 
plasma selenium levels and prostate cancer risk. In the case-control study by 
Brooks et al., low plasma selenium levels were associated with a four- to fivefold 
Method Name of author(s) Year of 
study
Sample RR 95% CI P.R.E 
outcome
Random control trials
Lippman et al. [132] 2009 Sel. Sup 1.04 0.90–1.18 4%
Dunn et al. [133] 2010 Sel. Sup 1.04 0.87–1.24 4%
Marshall et al. [134] 2011 Sel. Sup 1.09 0.93–1.27 9%
Klein et al. [16] 2011 Sel. Sup 0.90 0.93–1.27 10%
Algatar et al. [135] 2013 Sel. Sup 0.90 0.48–1.70 10%
Kristal et al. [42] 2014 Sel. Sup 1.25 0.79–1.98 25%
Cohort
Peters et al. [104] 2008 Sel. Sup 0.90 0.62–1.30 10%
Chan et al. [105] 2009 Plasma 1.35 0.99–1.84 35%
Geybels et al. [112] 2013 Nail 0.37 0.27–0.51 63%
Case-control
Allen et al. [136] 2008 Plasma 0.96 0.07–1.31 4%
Pourmand et al. 
[137]
2008 Serum 0.16 0.06–0.49 84%
Gill et al. [138] 2009 Serum 0.82 0.59–1.14 18%
Zhang et al. [139] 2009 Diet 1.30 0.30–5.70 30%
Outzen et al. [108] 2016 Plasma 1.01 0.94–1.08 1%
RR = relative risk, CI = confidence interval, P.R.E = percentage relative effect, Sel. Sup = selenium supplement.
Table 3. 
Showing studies on the effect of selenium on prostate cancer.
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elevated risk of prostate cancer [101]. In a retrospective cohort study, higher levels 
of selenium were associated with decreased risk of aggressive prostate cancer (RR 
0.60, 95% CI: 0.32–1.12), and the relationship at diagnosis may be modified by 
the manganese superoxide dismutase (SOD2) gene [105]. Furthermore, in a study 
involving the Within the Danish “Diet, Cancer and Health” cohort, higher levels of 
plasma selenium were not associated with lower risk of high-grade prostate cancer 
disease or prostate cancer-specific mortality [108]. A systematic review and meta-
analysis of case-control studies, randomized controlled trials, and prospective 
cohort studies showed decreased prostate cancer risk with increasing serum/plasma 
selenium levels (up to 170 ng/ml) when 12 studies were analyzed and also lower risk 
of disease with toenail selenium levels between 0.85 and 0.94 μg/g (estimated RR 
0.29, 95% CI: 0.14–0.61) in three high-quality studies [109]. Therefore, although 
there is evidence of a potential protective effect of selenium in terms of its status 
and supplementation, further studies are required especially in low-selenium status 
populations.
In the last 10 years, a number of systematic and meta-analysis have been con-
ducted to examine the relationship between selenium status and prostate cancer. 
In one study reported by Sayehmirj and colleagues, the relative risks for prostate 
cancer (based on case-control, cohort, and randomized control trials) on serum 
and nail samples were 0.85 (95% CI: 0.61–1.17) and 0.66 (95% CI: 0.41–1.05), 
respectively. They also reported a relative risk of 0.67 (95% CI: 0.52–0.87) between 
selenium levels and advanced prostate cancer [110]. The authors concluded that 
selenium supplementation could have a protective role against the initiation and 
progression to advanced stages [110]. A MOOSE-compliant meta-analysis of 17 
studies showed a significant inverse association between prostate cancer risk and 
serum selenium levels (RR 0.76, 95% CI: 0.64–0.76) [82].
Even though these studies suggest that higher levels of selenium are associated 
with decreased risk of prostate cancer; there are others that have demonstrated 
otherwise. An analysis of 15 prospective studies by Allen et al. failed to show any 
association between blood selenium levels and risk of prostate cancer (OR, 1.01, 
95% CI: 0.83–1.23). However, high blood selenium levels were not associated with 
nonaggressive disease, but with aggressive disease (OR 0.43, 95% CI: 0.21–0.87) 
[111]. Another key finding in this study was that nail selenium levels were signifi-
cantly inversely associated with prostate cancer risk (OR 0.29, 95% CI: 0.22–0.40, 
P < 0.001) and also with both aggressive and nonaggressive disease [111]. Similarly, 
in the prospective Netherlands cohort study, toenail selenium levels were associated 
with a significant reduction in the risk of advanced prostate cancer (RR 0.37, 95% 
CI: 0.27–0.51; P < 0.001) [112]. However, in a case-control study, selenium levels in 
toenail were not associated with prostate cancer risk, and its supplementation while 
not having any effect among participants with low selenium status elevates the 
risk (by 91%, P = 0.07) among those with higher selenium status [42]. The authors 
suggest that men with low selenium status did not benefit from its supplementation 
which increased the risk of high-grade prostate cancer among those participants 
with high selenium status [42].
The effects of selenium on prostate cancer remain uncertain. In a prospective 
cohort study in the United States, reported by Peter et al., showed that long-term 
selenium supplementation did not lower the overall risk of prostate cancer (HR 
0.90, 95% CI: 0.62–1.3) with participants having an average intake of >50 μg/day 
over a 10-year period [104]. In a Cochrane review including randomized controlled 
trials and longitudinal observational studies, there was no association between 
selenium supplementation and the risk of prostate cancer [113], nor in a Mendelian 
randomization analysis by Yarmolinsky et al. where the authors suggested that sele-
nium supplementation could have unfavorable effects on risks of advanced disease 
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[114]. There is further supporting evidence in the follow-up of the Procomb trial 
where there was no association between selenium supplementation and prostate 
cancer risk [115]. Conversely, there are studies that suggest caution with selenium 
supplement usage among males with prostate cancer. In the Health Professionals 
Follow-Up Study (over a 22-year period) of men diagnosed with nonmetastatic 
prostate cancer, supplementation of 140 or more μg/day of selenium had a 2.6-fold 
risk of prostate cancer mortality (95% CI: 1.44–4.70, P = 0.001) compared with 
nonusers [116].
The mechanism of action of selenium in the inhibition of cancer development 
could include reduction in DNA damage. Waters et al. reported that dietary supple-
mentation of selenium increases epithelial cell apoptosis in prostate and DNA 
damage in prostate tissue [117].
7. Vitamin C and prostate cancer
Vitamin C is mainly obtained from vegetables and fruit sources and is consid-
ered to be a very important water-soluble antioxidant [118]. Foods and supplements 
are sources, which provide vitamin C intake while that from foods only is referred 
to as dietary vitamin C. There is evidence that the mechanisms by which vitamin C 
prevents the harmful effects of carcinogens include decreasing oxidative DNA dam-
age [119, 120]. Vitamin C functions as a scavenger of free radicals and, therefore, 
has a potential role in the chemoprevention of prostate cancer [121]. Animal and 
in vitro studies have demonstrated that it could inhibit the cell growth and viability 
[8]. Menon and colleagues suggested that vitamin C may be a potent anticancer 
agent as it inhibits tumor growth by producing reactive oxygen species [122]. In 
another study, vitamin C inhibits cell growth and division via the generation of 
hydrogen peroxide, which eventually damages the cell [123].
A number of epidemiological studies have documented the relationship between 
risk of prostate cancer and vitamin C intake; however, the findings have been 
inconclusive [48, 66, 124, 125]. In a case-control study conducted in Italy involving 
men with incident, histologically confirmed prostate cancer, there was a significant 
inverse association (OR 0.78, 95% CI: 0.58–0.96; P = 0.02), especially among men 
with the highest vitamin C intake [125]. Similar findings were reported in another 
case-control study where vitamin C decreased prostate cancer risks among men in 
the highest quartile of intake of the antioxidant (OR 0.49, 95% CI: 0.33–0.74) [66]. 
There are two other case control studies that have reported reduced prostate cancer 
risk due to vitamin C intake [48, 126]. There is also evidence in prospective stud-
ies such as the North Carolina-Louisiana Prostate Cancer Project where >1500 mg 
(compared with <500 mg vitamin C equivalent/day) reduced prostate cancer risk 
(RR 0.31, 95% CI: 0.15–0.67; P < 0.01) [127] (Table 4). In meta-analysis conducted 
by Bai and colleagues involving 103,658 subjects, dietary vitamin C intake (150 mg/
day) reduced risk among case-control studies (RR 0.79, 95% CI: 0.69–0.91, 
P = 0.001) and 0.95 (95% CI: 0.90–0.99, P = 0.039) in cohort studies [125].
However, a number of studies have reported no association between prostate 
cancer risk and vitamin C [14, 128]. In The Prostate Cancer and Environment Study 
(PROtEuS), a recent population-based case-control study conducted in Montreal, 
there was the absence of an association between overall or grade of prostate cancer 
incidence and either recent dietary or supplemented vitamin C uptake [129]. Key 
evidence also comes from the posttrial follow-up in the Physicians’ Health Study 
II randomized trial where no effect was observed of vitamin C on incidence of 
prostate cancer (HR 0.99, 95% CI: 0.89–1.10) [14]. Earlier in the Physicians’ Health 
Study II randomized controlled trial, vitamin C supplement (500 mg daily) had 
Antioxidants
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no effect on prostate cancer (HR 1.02, 95% CI: 0.90–1.15; P = 0.80), a finding that 
remained even after stratification by various cancer risk factors [128]. Further, a 
systematic review of nine randomized controlled trials found no significant effects 
of vitamin C supplementation (RR 0.98, 95% CI: 0.91–1.06) on prostate cancer 
incidence [130] (Table 4).
Studies involving the use of supplements might favor results that are bias as the 
period of use may be relatively short term, associated health problems in persons 
who use vitamin C supplements, and the different biological activity or absorption 
contributing to the possibly different effects of dietary compared with supplemen-
tal use of vitamin C [121, 131].
The studies cited above on vitamin C and prostate cancer risk provide incon-
clusive evidence. While some case-control studies demonstrate a protective effect, 
randomized trials and meta-analysis fail to clearly demonstrate any beneficial effect 
of vitamin C on the risk of prostate cancer.
8. Conclusion
The effect of dietary and supplemental antioxidants on risk of prostate cancer 
remains undecided and inconclusive. More epidemiological and human clinical 
trials as well as animal studies are needed to give an improved understanding on the 
biology of prostate cancer and how antioxidants at supranutritional and nutritional 
levels influence the risk of prostate cancer.
Nothing to disclose
The authors have no funding and conflicts of interest to disclose regarding the 
content of this chapter.
Method Name of author(s) Year of 
study
Sample Risk 95% CI P.R.E 
outcome
Case-control
Bidoli et al. [124] 2009 Diet OR = 0.86 0.65–1.08 14%
McCann et al. [66] 2005 Diet OR = 0.49 0.33–0.74 51%
Deneo-Pellegrini 
et al. [126]
1999 Diet OR = 0.40 0.0.20–
0.80
60%
Vance et al. [127] 2016 Sup. OR = 0.31 0.15–0.67 69%
Parent et al. [129] 2018 Diet OR = 0.95 0.77–1.18 5%
Cohort
Gaziano et al. [128] 2009 Sup. HR = 1.02 0.90–1.15 2%
Wang et al. [14] 2014 Sup. OR = 1.03 0.93–1.15 2%
Meta-analysis
Bai et al. [125] 2015 Sup. RR = 0.91 0.84–0.98 9%
Jiang et al. [130] 2010 Sup. RR = 0.98 0.91–1.06 2%
RR = relative risk, OR = odds ratio, CI = confidence interval, P.R.E = percentage relative effect, Sup. = supplement.
Table 4. 
Showing studies on the effect of vitamin C on prostate cancer.
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